Tivic Health Systems, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
1.010
-0.390 (-27.86%)
At close: Apr 28, 2026 - Market closed
Company Description
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company.
Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications.
In addition, it offers CDMO services. The company was incorporated in 2016 and is based in Fremont, California.
Tivic Health Systems, Inc.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | Michael Handley |
Contact Details
Address: 47685 Lakeview Blvd. Fremont, California 94538 United States | |
| Phone | 888 276 6888 |
| Website | tivichealth.com |
Stock Details
| Ticker Symbol | VBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001438943 |
| CUSIP Number | 92849B107 |
| ISIN Number | US92849B1070 |
| Employer ID | 75-3268988 |
Key Executives
| Name | Position |
|---|---|
| Michael R. Cavanaugh CPA, J.D. | Chief Executive Officer and Director |
| Hon. Edward Farrell Feighan | Executive Chairman |
| Dr. Brandon Joel Zipp Ph.D. | Scientific Co-Founder and Chief Science Officer |
| Richard McKilligan J.D., M.B.A. | Chief Financial Officer, Counsel and Secretary |
| Dr. J. Jeremiah Mann | Vice President of Operations and Senior Agronomist |
| Dr. Dong Yuejin | Partner |